Navigation Links
Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
Date:10/26/2007

SOUTH SAN FRANCISCO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, today announced that management will hold an investor conference call on Thursday, November 1, 2007 at 10:30 a.m. ET/7:30 a.m. PT to discuss financial results for the third quarter 2007.

Individual and institutional investors can access the call via (888) 297-0358 (U.S. and Canada) or (719) 325-2215 (international). To access the live audio webcast or the subsequent archived recording, visit the "Investors and Media -- Calendar of Events" section of the Sunesis website at http://www.sunesis.com. Please log on to Sunesis' website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
4. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
5. Signal Transduction Reporting Systems Using Cis-Acting Enhancer Elements
6. Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion Transactivators
7. Versatile Reporter Vectors for Monitoring Viral Transduction
8. In Vivo Signal Transduction Pathway Reporting Systems
9. Improved Vectors for PathDetect Trans-Reporting Systems
10. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
11. Cis-Reporting System Monitors Intracellular Calcium Mobilization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Shimadzu Scientific Instruments ... multipurpose UV-visible spectrophotometer. Offering wavelength scanning from 190 ... ideal for applications in a variety of industries, ... The user-friendly UV-1280 enables intuitive operation, while the ...
(Date:1/22/2015)... The laboratory information management systems market is ... of technological advancements due to factors such as rising ... integrate healthcare systems, and increasing government support for adoption ... Key players in the market focus on technological advancements ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was invited to ... on probiotics in San Diego, CA. , The Scripps ... health care professionals. This year’s pre-conference seminar was held on ... Dr. Leyer spoke about the emerging topics and science in ...
(Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, ... Sequenom, Inc. (NASDAQ: SQNM ), the ... agreement for next generation noninvasive prenatal tests (NIPT). ... interpretation technology, called Mantis™, to advance analysis of ...
Breaking Biology Technology:Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4
... May 12 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) announced ... present at the Rodman & Renshaw Annual Global Investment Conference taking place in ... , , ... Summer Time ( 5:15 a.m. Eastern Daylight Time ) on Tuesday, May ...
... May 12 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. ... drug development company specialized in oncology and endocrine ... Drug Administration (FDA) has approved the Company,s Investigational ... conjugate compound, AEZS-108, in luteinizing hormone releasing hormone ...
... 2010 , , , ... New Outcomes Trial to Expand Evidence for Dronedarone in a Different AF,Population , ... Sanofi-aventis (EURONEXT: SAN and NYSE: ... to assess the potential clinical benefit of Multaq(R) (dronedarone),in over 10, 000 patients with ...
Cached Biology Technology:Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer 2Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer 3Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 2Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 3Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 4Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 5Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 6Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 7Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 8Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 9Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 10
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today its completion ... its adherence to current U.S. Food and Drug Administration ... smart device and smart phone application trials utilizing the ... "HITLAB is determined to improve global healthcare access, ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ...  report to their offering. One major ... With continuous advances in technology, it is important to ...
(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... biofuel? Now that a University of Illinois metabolic engineer has ... of fermenting galactose, the answer is an unequivocal yes. ... miscanthus, and switchgrass. ln small island or peninsular nations, though, ... a U of I assistant professor of microbial genomics and ...
... found a key to keeping stem cells in their neutral ... published in the journal PLoS One , the researchers ... soft gel rather than on a hard plate or dish ... the ability to become any type of tissue. The soft ...
... 15, 2010 For Immediate Release The Scripps ... (UCSD) School of Medicine have been awarded approximately $7.5 ... could eventually become drug candidates for the treatment of ... funds awarded, $5 million will go to Scripps Research, ...
Cached Biology News:Seaweed as biofuel? Metabolic engineering makes it a viable option 2Soft substrate promotes pluripotent stem cell culture 2Soft substrate promotes pluripotent stem cell culture 3Team awarded $7.5 million to identify potential drug candidates to treat nicotine addiction 2Team awarded $7.5 million to identify potential drug candidates to treat nicotine addiction 3
JTV1 gene...
APO-BrdU™ TUNEL Assay Kit *with Alexa Fluor® 488 anti-BrdU* *60 assays*...
The FlowTACS Apoptosis Detection Kit is designed specifically for in situdetection of apoptotic...
Recombinant Rat PTX2/SAP...
Biology Products: